GENOCEA BIOSCIENCES, INC.

(GNCA)
  Report
Delayed Nasdaq  -  05/18 04:00:00 pm EDT
0.2421 USD   +7.60%
05/05GENOCEA BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
05/05Genocea Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/29Top Premarket Decliners
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Genocea Biosciences : H.C. Wainwright BIOCONNECT Virtual Conference

01/08/2022 | 07:18pm EDT
H.C. Wainwright BIOCONNECT Virtual Conference

Disclaimer

Genocea Biosciences Inc. published this content on 10 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 January 2022 00:17:04 UTC.


ę Publicnow 2022
All news about GENOCEA BIOSCIENCES, INC.
05/05GENOCEA BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
05/05Genocea Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31..
CI
04/29Top Premarket Decliners
MT
04/29HC Wainwright Downgrades Genocea Biosciences to Neutral From Buy
MT
04/29Stifel Downgrades Genocea Biosciences to Hold From Buy, Adjusts Price Target to $0.16 F..
MT
04/28GENOCEA BIOSCIENCES : Initiates Restructuring and Announces Plan to Explore Strategic Alte..
PU
04/28Genocea Announces Plan to Explore Strategic Alternatives
CI
04/28GENOCEA BIOSCIENCES, INC. : Costs Associated with Exit or Disposal Activities, Regulation ..
AQ
04/28Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives
AQ
04/11TRANSCRIPT : Genocea Biosciences, Inc. Presents at AACR Annual Meeting 2022, Apr-08-2022 t..
CI
More news
Analyst Recommendations on GENOCEA BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 0,57 M - -
Net income 2022 -40,5 M - -
Net cash 2022 12,0 M - -
P/E ratio 2022 -0,42x
Yield 2022 -
Capitalization 14,2 M 14,2 M -
EV / Sales 2022 3,94x
Capi. / Sales 2023 -
Nbr of Employees 74
Free-Float 93,7%
Chart GENOCEA BIOSCIENCES, INC.
Duration : Period :
Genocea Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENOCEA BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 0,24 $
Average target price 3,08 $
Spread / Average Target 1 172%
EPS Revisions
Managers and Directors
William D. Clark President, Chief Executive Officer & Director
Diantha Duvall Chief Financial Officer
Kenneth M. Bate Chairman
Jessica Baker Flechtner Chief Scientific Officer
Thomas Andrew Davis Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
GENOCEA BIOSCIENCES, INC.-79.13%13
MODERNA, INC.-45.78%56 593
LONZA GROUP AG-27.42%41 313
IQVIA HOLDINGS INC.-30.08%39 122
SEAGEN INC.-7.50%26 976
ICON PUBLIC LIMITED COMPANY-34.37%17 002